At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a study that was designed to determine whether seropositivity to a panel of tumour antigens was associated with a risk of relapse in patients with stage II and III melanoma.
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse
11th December 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now